发明名称 |
Formulation comprising buprenorphine |
摘要 |
<p>Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C ther , of 0.2 ng/ml or greater which is maintained for a duration T maint of at least 2 hours.</p> |
申请公布号 |
EP1878446(A2) |
申请公布日期 |
2008.01.16 |
申请号 |
EP20070020868 |
申请日期 |
2003.03.19 |
申请人 |
VERNALIS (R&D) LIMITED;ARCHIMEDES DEVELOPMENT LIMITED |
发明人 |
BIRCH, PHILIP, JOHN;HAYES, ANN, GAIL;WATTS, PETER, JAMES;CASTILE, JONATHAN, DAVID |
分类号 |
A61K9/08;A61K47/36;A61K9/00;A61K9/12;A61K31/195;A61K31/196;A61K31/405;A61K31/407;A61K31/485;A61K31/54;A61K31/5415;A61K45/00;A61K47/02;A61K47/10;A61K47/14;A61K47/18;A61K47/26;A61K47/34;A61K47/38;A61M11/00;A61M15/08;A61P5/24;A61P15/00;A61P25/02;A61P25/04;A61P27/16;A61P29/00;A61P43/00 |
主分类号 |
A61K9/08 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|